Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from oral rivastigmine capsules to transdermal patch in Alzheimer's disease
2006-006182-16Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Novartis. Primary endpoint: Gastrointestinal adverse events. Started May 2007; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-006182-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006182-16.